Showing results (1-10 of 14) with videos related to

Sort By:
Pageof 2
Physics in Medicine and Biology|February 1, 2017
Two dimensional magnetic particle spectrometryM Graeser, A von Gladiss, M Weber, et al.
Physics in Medicine and Biology|May 25, 2019
Correction of linear system drifts in magnetic particle imagingT Knopp, N Gdaniec, R Rehr, et al.
Virchows Archiv : an International Journal of Pathology|April 22, 2009
Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancerM Graeser, K Bosse, M Brosig, et al.
Physics in Medicine and Biology|April 6, 2017
Hybrid system calibration for multidimensional magnetic particle imagingA von Gladiss, M Graeser, P Szwargulski, et al.
ESMO Open|November 28, 2025
Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registryU Nitz, M Graeser, O Gluz, et al.
Biomaterials Science|October 8, 2025
Approaching the physical limits of specific absorption rate for synthetic antiferromagnetic nanodisks in hyperthermia applicationsS Scheibler, H Wei, J Ackers, et al.
Journal of Cancer Research and Clinical Oncology|March 4, 2021
Sphingosine-kinase-1 expression is associated with improved overall survival in high-grade serous ovarian cancerL C Hanker, A El-Balat, Z Drosos, et al.
Nature Communications|April 28, 2019
Human-sized magnetic particle imaging for brain applicationsM Graeser, F Thieben, P Szwargulski, et al.
ESMO Open|November 22, 2025
Integrative analysis of RNA expression signatures and recurrent genomic alterations before treatment: link to menopausal status, short-term endocrine therapy response and disease-free survival in luminal breast cancerG Zhang, H Ni, L Mishieva, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 16, 2023
Nab-paclitaxel weekly versus dose-dense solvent-based paclitaxel followed by dose-dense epirubicin plus cyclophosphamide in high-risk HR+/HER2- early breast cancer: results from the neoadjuvant part of the WSG-ADAPT-HR+/HER2- trialO Gluz, S Kuemmel, U Nitz, et al.
Pageof 2